Akèy › Kansè ovè › South Dakota
Etid klinik pou Kansè ovè nan South Dakota
16 etid pou Kansè ovè ap chèche patisipan nan sit nan South Dakota.
Vil nan South Dakota
Tèks ofisyèl etid la (Anglè)
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Sanford Health, Sioux Falls
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Oct 5, 2026 · NCT06915025Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 5, 2026 · NCT05564377A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Avera Medical Group, Sioux Falls
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Sanford Cancer Center /ID# 274901, Sioux Falls
- Avera Cancer Institute - Sioux Falls /ID# 276226, Sioux Falls
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0132 - Avera Cancer Institute, Sioux Falls
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05128825A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Avera Cancer Institute - Sioux Falls /ID# 278627, Sioux Falls
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07059845Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Sanford Cancer Center-Sioux Falls, Sioux Falls
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT07214779Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Avera Cancer Institute Sioux Falls, Sioux Falls
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 14, 2026 · NCT06787612A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0112, Sioux Falls
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Aug 12, 2026 · NCT07546500A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Ap rekrite
Laj 35 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Avera Cancer Institute-Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute at Pierre, Pierre
- ak 4 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Sanford Cancer Center Gynecologic Oncology, Sioux Falls
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06161025A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Sanford Cancer Center, Sioux Falls
- Sanford USD Medical Center, Sioux Falls
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Avera Medical Group Gynecologic, Sioux Falls
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 2, 2026 · NCT06819007A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Avera Cancer Institute, Sioux Falls
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996Avera Cancer Sequencing and Analytics Protocol (ASAP)
- Avera Cancer Institute - Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute - Pierre, Pierre
- ak 2 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 27, 2026 · NCT05142033Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.